(Human) HER2 Antibody - Trastuzumab IgG4 (S228P) Isotype

Anti-HER2 (CD340) - Human IgG4 (S228P) for low effector function

Anti-HER2-Tra-hIgG4 (S228P) is a Trastuzumab-based research antibody. Trastuzumab is humanized IgG1 monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). HER2, also known as ERBB2 or HER2/neu, plays an important role in normal cell growth and differentiation [1]. Particularly in breast and ovarian cancers, HER2 is over-expressed and causes uncontrollable cell proliferation. Binding of trastuzumab to HER2 results in cell death through different mechanisms, including antibody-dependent cell-mediated cytotoxicity and phagocytosis [2, 3]. Trastuzumab has been approved by the FDA for the treatment of breast cancer.

Anti-HER2-Tra-hIgG4 (S228P) comprises the variable region of Trastuzumab fused to an engineered human IgG4 constant region mediating low effector functions. It contains an engineered hinge region mutation (S228P) designed to prevent the exchange of IgG4 molecules. For applications requiring high Fc effector activity, InvivoGen also offers Anti-HER2-Tra-hIgG1, a biosimilar research antibody to Trastuzumab. 

This mAb can be used together with InvivoGen's Raji-HER2 cell line to study antibody-dependent effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), either with peripheral blood mononuclear cells or T cell-derived Jurkat reporter cells (see figure).

Key features

• Each lot is functionally tested and validated.
• The complete sequence of the antibody construct was verified.
• The absence of endotoxins is determined by the EndotoxDetect™ assay.

References:

1. Rubin I. & Yarden Y. 2001. The basic biology of HER2. Ann Oncol.12 Suppl 1:S3-8.
2. Collins DM. et al., 2012. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 23(7):1788-95.
3. Petricevic B. et al., 2013. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 11:307.